Interplay between age, cerebral small vessel disease, parenchymal amyloid-β, and tau pathology: Longitudinal studies in hypertensive stroke-prone rats

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S205-S215

  Schreiber, Stefanie ^a,b   Drukarch, Benjamin ^c   Garz, Cornelia ^a   Niklass, Solveig ^a   Stanaszek, Luiza ^b   Kropf, Siegfried ^a   Bueche, Celine ^b   Held, Friederike ^a   Vielhaber, Stefan ^a,b   Attems, Johannes ^d   Reymann, Klaus G ^b,e   Heinze, Hans Jochen ^a,b,e   Carare, Roxana O ^f   Wilhelmus, Micha M M ^c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c Department of Anatomy and Neurosciences Cellular Neuropharmacology Group Neuroscience Campus Amsterdam   (Netherlands)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e LEIBNIZ INSTITUTE FOR NEUROBIOLOGY   (Germany)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Amyloid ; amyloid protein precursor; cerebral small vessel disease; hyperphosphorylated tau; spontaneously hypertensive stroke prone rats

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; TAU PROTEIN; LECTIN; PLASMA PROTEIN;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BASAL GANGLION; BLOOD BRAIN BARRIER; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS CALLOSUM; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION; WESTERN BLOTTING; AGING; ANIMAL; BLOOD; BRAIN; COMPLICATION; DIAGNOSTIC USE; DISEASE MODEL; DURA MATER; METABOLISM; PATHOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; THROMBOCYTE; WISTAR RAT;

AGING; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD PLATELETS; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; BRAIN; CEREBRAL SMALL VESSEL DISEASES; DISEASE MODELS, ANIMAL; DURA MATER; LECTINS; LONGITUDINAL STUDIES; RATS; RATS, INBRED SHR; RATS, WISTAR; TAU PROTEINS;

EID: 84920596641     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132618     Document Type: Conference Paper

References (60)

1. Grinberg LT, Thal DR (2010) Vascular pathology in the aged human brain. Acta Neuropathol 119, 277-290.
2. Thompson CS, Hakim AM (2009) Living beyond our physiological means: Small vessel disease of the brain is an expression of a systemic failure in arteriolar function: A unifying hypothesis. Stroke 40, e322-e330.
3. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen C, Smith C, van Buchem M, Norrving B, Gorelick PB, DichgansM(2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12, 822-838.
4. Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten EC, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T (2011) Incident lacunes influence cognitive decline: The LADIS study. Neurology 76, 1872-1878.
5. Lo RY, Jagust WJ (2012) Vascular burden and Alzheimer disease pathologic progression. Neurology 79, 1349-1355.
6. Yakushiji Y, Noguchi T, Hara M, Nishihara M, Eriguchi M, Nanri Y, Nishiyama M, Hirotsu T, Nakajima J, Kuroda Y, Hara H (2012) Distributional impact of brain microbleeds on global cognitive function in adults without neurological disorder. Stroke 43, 1800-1805.
7. Braun H, Schreiber S (2013) Microbleeds in cerebral small vessel disease. Lancet Neurol 12, 735-736.
8. Schreiber S, Bueche CZ, Garz C, Kropf S, Angenstein F, Goldschmidt J, Neumann J, Heinze HJ, Goertler M, Reymann KG, Braun H (2012) The pathologic cascade of cerebrovascular lesions in SHRSP: Is erythrocyte accumulation an early phase? J Cereb Blood Flow Metab 32, 278-290.
9. Schreiber S, Bueche CZ, Garz C, Braun H (2013) Blood brain barrier breakdown as the starting point of cerebral small vessel disease?-New insights from a rat model. Exp Transl Stroke Med 5, 4.
10. Wardlaw JM, Sandercock PA, Dennis MS, Starr J (2003) Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 34, 806-812.
11. Wardlaw JM (2010) Blood-brain barrier and cerebral small vessel disease. J Neurol Sci 299, 66-71.
12. Wardlaw JM, Smith C, Dichgans M (2013) Mechanisms of sporadic cerebral small vessel disease: Insights from neuroimaging. Lancet Neurol 12, 483-497.
13. WardlawJ, Smith C, DichgansM(2013) Microbleeds in cerebral small vessel disease-authors' reply. Lancet Neurol 12, 736-737.
14. Attems J, Jellinger KA (2013) Amyloid and tau: Neither chicken nor egg but two partners in crimel. Acta Neuropathol 126, 619-621.
15. Jellinger KA, Attems J (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 229-230 37-41.
16. Jellinger KA, Attems J (2010) Is there pure vascular dementia in old age? J Neurol Sci 299, 150-154.
17. Jellinger KA, Attems J (2010) Prevalence and pathology of vascular dementia in the oldest-old. J Alzheimers Dis 21, 1283-1293.
18. Jellinger KA, Attems J (2010) Prevalence of dementia disorders in the oldest-old: An autopsy study. Acta Neuropathol 119, 421-433.
19. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, Zlokovic B, Yan SS, Lembo G (2012) Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60, 188-197.
20. Reed B, Villeneuve S, Mack W, Decarli C, Chui HC, Jagust W(2014) Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 71, 195-200.
21. Rodrigue KM, Rieck JR,Kennedy KM, DevousMDSr, Diaz-Arrastia R, Park DC (2013) Risk factors for beta-amyloid deposition in healthy aging: Vascular and genetic effects. JAMA Neurol 70, 600-606.
22. Williams VJ, Leritz EC, Shepel J, McGlinchey RE, Milberg WP, Rudolph JL, Lipsitz LA, Salat DH (2013) Interindividual variation in serum cholesterol is associated with regional white matter tissue integrity in older adults. Hum Brain Mapp 34, 1826-1841.
23. Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO (2013) Cerebral amyloid angiopathy, Prion angiopathy, CADASIL and the spectrum of protein elimination-failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol 39, 593-611.
24. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738.
25. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
26. Jagust W (2013) Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 77, 219-234.
27. Zlokovic BV (2010) Neurodegeneration and the neurovascular unit. Nat Med 16, 1370-1371.
28. Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol 70, 960-969.
29. Chetelat G (2013) Alzheimer disease: Abeta-independent processes-rethinking preclinical AD. Nat Rev Neurol 9, 123-124.
30. Jack CR Jr, Knopman DS,Weigand SD,Wiste HJ, Vemuri P, LoweV, Kantarci K, Gunter JL, SenjemML,Ivnik RJ, Roberts RO, RoccaWA, BoeveBF, PetersenRC(2012)Anoperational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71, 765-775.
31. Jack CR Jr, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, Mielke MM, Jones DT, Senjem ML, Gunter JL, Gregg BE, Pankratz VS, Petersen RC (2013) Amyloidfirst and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81, 1732-1740.
32. Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, Rabinovici GD, Jagust WJ (2013) Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70, 1512-1519.
33. Chao LL, Decarli C, Kriger S, Truran D, Zhang Y, Laxamana J, Villeneuve S, Jagust WJ, Sanossian N, Mack WJ, Chui HC, Weiner MW (2013) Associations between white matter hyperintensities and beta amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLoS One 8, e65175.
34. Haight TJ, Landau SM, Carmichael O, Schwarz C, Decarli C, Jagust WJ (2013) Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol 70, 1039-1045.
35. Marchant NL, Reed BR, DeCarli CS, Madison CM, Weiner MW, Chui HC, Jagust WJ (2012) Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiol Aging 33, 1006-1036.
36. Anand A, Banik A, Thakur K, Masters CL (2012) The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation. Curr Alzheimer Res 9, 1010-1029.
37. Csiszar A, Tucsek Z, Toth P, Sosnowska D, Gautam T, Koller A, Deak F, Sonntag WE, Ungvari Z (2013) Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in beta-amyloid generation and Alzheimer's disease. Am J Physiol Heart Circ Physiol 305, H1120-H1130.
38. Liu H, Xing A, Wang X, Liu G, Li L (2012) Regulation of beta-amyloid level in the brain of rats with cerebrovascular hypoperfusion. Neurobiol Aging 33, 826-842.
39. Ndung'u M, Hartig W, Wegner F, Mwenda JM, Low RW, Akinyemi RO, Kalaria RN (2012) Cerebral amyloid beta(42) deposits and microvascular pathology in ageing baboons. Neuropathol Appl Neurobiol 38, 487-499.
40. Jiwa NS, Garrard P, Hainsworth AH (2010) Experimental models of vascular dementia and vascular cognitive impairment: A systematic review. J Neurochem 115, 814-828.
41. Braun H, Bueche CZ, Garz C, Oldag A, Heinze HJ, Goertler M, Reymann KG, Schreiber S (2012) Stases are associated with blood-brain barrier damage and a restricted activation of coagulation in SHRSP. J Neurol Sci 322, 71-76.
42. Mencl S, Garz C, Niklass S, Braun H, Goeb E, Homola G, Heinze H-J, Reymann K, Kleinschnitz C, Schreiber S (2013) Early microvascular dysfunction in cerebral small vessel disease is not detectable on 3.0 Tesla magnetic resonance imaging: A longitudinal study in spontaneously hypertensive stroke-prone rats. Exp Transl Stroke Med 5, 8.
43. Niklass S, Stoyanov S, Garz C, Bueche CZ, Mencl S, Reymann K, Heinze HJ, Carare RO, Kleinschnitz C, Schreiber S (2014) Intravital imaging in spontaneously hypertensive stroke-prone rats-a pilot study. Exp Transl Stroke Med 6, 1.
44. Bueche CZ, Hawkes C, Garz C,Vielhaber S, Attems J, Knight RT, Reymann K, Heinze H-J, Carare RO, Schreiber S (2014) Hypertension drives parenchymal beta-amyloid accumulation in the brain parenchyma. Ann Clin Transl Neurol 1, 124-129.
45. Michalski D, Grosche J, Pelz J, Schneider D,Weise C, Bauer U, Kacza J, Gartner U, Hobohm C, HartigW(2010) A novel quantification of blood-brain barrier damage and histochemical typing after embolic stroke in rats. Brain Res 1359, 186-200.
46. Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, Song Y, Andreadis A, Fu Y, Brady ST, Binder LI (2011) Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci 31, 9858-9868.
47. Verhaar R, Drukarch B, Bol JG, Jongenelen CA, Musters RJ, Wilhelmus MM (2012) Increase in endoplasmic reticulumassociated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease. Neurobiol Dis 45, 839-850.
48. Wilhelmus MM, Otte-Holler I, Wesseling P, de Waal RM, Boelens WC, Verbeek MM (2006) Specific association of small heat shock proteins with the pathological hallmarks of Alzheimer's disease brains. Neuropathol Appl Neurobiol 32, 119-130.
49. Iadecola C (2013) The pathobiology of vascular dementia. Neuron 80, 844-866.
50. Jellinger KA (2007) The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 113, 349-388.
51. Lin B, Schmidt-Kastner R, Busto R, Ginsberg MD (1999) Progressive parenchymal deposition of beta-amyloid precursor protein in rat brain following global cerebral ischemia. Acta Neuropathol 97, 359-368.
52. Chalmers K,Wilcock G, Love S (2005) Contributors to white matter damage in the frontal lobe in Alzheimer's disease. Neuropathol Appl Neurobiol 31, 623-631.
53. Selnes P, Blennow K, Zetterberg H, Grambaite R, Rosengren L, Johnsen L, Stenset V, Fladby T (2010) Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res 7, 10.
54. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
55. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201.
56. Jellinger KA, Attems J (2012) Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol 31, 87-98.
57. Klunk WE, Perani D (2013) Amyloid and neurodegeneration: Converging and diverging paths. Neurology 81, 1728-1729.
58. Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, Mack WJ, Decarli C,WeinerMW, Mungas DM, Chui HC, Jagust WJ (2013) The aging brain and cognition: Contribution of vascular injury and abeta to mild cognitive dysfunction. JAMA Neurol 70, 488-495.
59. Ley K, Pries AR, Gaehtgens P (1986) Topological structure of rat mesenteric microvessel networks. Microvasc Res 32, 315-332.
60. Yang ST, Mayhan WG, Faraci FM, Heistad DD (1991) Mechanisms of impaired endothelium-dependent cerebral vasodilatation in response to bradykinin in hypertensive rats. Stroke 22, 1177-1182.